This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

9 Meters Biopharma Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Bethany Sensenig

Algemeen directeur

US$1.3m

Totale compensatie

Percentage CEO-salaris	35.7%
Dienstverband CEO	1.5yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	2.9yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Bethany Sensenig's beloning veranderd ten opzichte van 9 Meters Biopharma's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Mar 31 2023	n/a	n/a	-US$46m
Dec 31 2022	US$1m	US$457k	-US$44m

Compensatie versus markt: De totale vergoeding ($USD 1.28M ) Bethany } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 476.59K ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Bethany te vergelijken met de prestaties van het bedrijf.

CEO

Bethany Sensenig (47 yo)

1.5yrs

Tenure

US$1,279,586

Compensatie

Ms. Bethany Sensenig MBA, CMA, serves as Interim Chief Executive Officer of 9 Meters Biopharma, Inc. since May 30, 2023. She serves as a Chief Financial Officer at 9 Meters Biopharma, Inc. since January 15...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Lorin Johnson	Independent Director	5.5yrs	US$84.70k	0.057% € 4.5k
Mark Sirgo	Independent Chairman	3.3yrs	US$119.70k	0.57% € 46.0k
Mark Pimentel	Member of Scientific Advisory Board	2.9yrs	geen gegevens	geen gegevens
Michael Rice	Independent Director	2.4yrs	US$78.45k	0.027% € 2.2k
Michael Constantino	Independent Director	3.1yrs	US$82.20k	0.048% € 3.9k
Z. Falchuk	Member of Scientific Advisory Board	2.9yrs	geen gegevens	geen gegevens
Maureen Leonard	Member of Scientific Advisory Board	2.9yrs	geen gegevens	geen gegevens
Russel Cohen	Member of Scientific Advisory Board	2.9yrs	geen gegevens	geen gegevens
Benjamin Lebwohl	Member of Scientific Advisory Board	2.9yrs	geen gegevens	geen gegevens
Charles Randall	Member of Scientific Advisory Board	2.9yrs	geen gegevens	geen gegevens
Samantha Ventimiglia	Independent Director	1.8yrs	US$67.20k	0.027% € 2.2k

2.9yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 2Q3A wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.9 jaar), wat duidt op een nieuw bestuur.

This company listing is no longer active

9 Meters Biopharma Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

9 Meters Biopharma, Inc. Appoints Bethany Sensenig as Interim CEO

9 Meters Biopharma, Inc. Announces the Resignation of John Temperato as President

High number of new and inexperienced directors

9 Meters Biopharma, Inc., Annual General Meeting, Jun 22, 2022

High number of new and inexperienced directors

President recently bought €50k worth of stock

Recent updates

9 Meters Biopharma Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Rule

9 Meters Biopharma, Inc. Appoints Bethany Sensenig as Interim CEO

9 Meters Biopharma, Inc. Announces the Resignation of John Temperato as President

9 Meters Biopharma, Inc. Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome

High number of new and inexperienced directors

9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA for Vurolenatide in Short Bowel Syndrome

9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome

9 Meters Biopharma, Inc. announced that it expects to receive $70 million in funding

9 Meters Biopharma, Inc., Annual General Meeting, Jun 22, 2022

High number of new and inexperienced directors

President recently bought €50k worth of stock

9 Meters Biopharma Provides Clinical Update on Late-Stage Pipeline Products Vurolenatide for Short Bowel Syndrome and Larazotide for Celiac Disease

Independent Chairman recently bought €84k worth of stock

9 Meters Biopharma, Inc. Announces Initiation of Phase 2 Vibrant Study of Vurolenatide for Short Bowel Syndrome

9 Meters Biopharma, Inc. Announces Publication in Journal of Clinical Investigation Describing Successful Use of Larazotide for Treating Multisystem Inflammatory Syndrome in Children Resulting from Covid-19 Infection

9 Meters Biopharma, Inc. Receives USAN Approval to Use the Designated Nonproprietary Name Vurolenatide for Its Long-Acting GLP-1 Agonist for Short Bowel Syndrome

Forecast to breakeven in 2024

9 Meters Biopharma Hosting Key Opinion Leader Webinar on Short Bowel Syndrome and NM-002 Program Update

9 Meters Biopharma Inc Appoints Michael Rice as Board of Director

New 90-day high: €1.86

9 Meters Biopharma, Inc. Announces the Resignation of Nissim Darvish as Director

Independent Director has left the company

New 90-day high: €1.22

New 90-day high: €1.19

9 Meters Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $30.000001 million.

New 90-day high: €0.85

9 Meters Biopharma Announces Positive Preclinical Data for NM-102, a Gut Microbiome Modulator in an Immune Checkpoint Inhibitor Failure Model

Independent Chairman recently bought €81k worth of stock

New 90-day high - €0.74

Innovate Biopharmaceuticals, Inc. (NasdaqCM:INNT) completed the acquisition of RDD Pharma, Ltd. from OrbiMed Israel Partners managed by OrbiMed Advisors, L.L.C. and others.

9 Meters Biopharma, Inc.(NasdaqCM:NMTR) dropped from Russell Microcap Index

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd